XiaoEr LianHuaQinqGan alleviates viral pneumonia in mice infected by influenza A and respiratory syncytial viruses. (31st December 2022)

• Record Type: Journal Article
• Authors: Li, Wenyan; Li, Tongtong; Zhao, Chi; Song, Tao; Mi, Yao; Chuangfeng, Zhang; Hou, Yunlong; Jia, Zhenhua
• Is Part Of: Pharmaceutical biology. Volume 60:Number 1(2022)
• Page Start: 2355
• Page End: 2366
• Publication Date: 2022-12-31
• Subjects: Xiaoer lianhuaqinggan(XELH) -- antiviral effects -- anti-inflammatory effects -- immunoregulatory effects; Pharmacognosy -- Periodicals; Materia medica, Vegetable -- Periodicals; 615.321
• DOI: 10.1080/13880209.2022.2147961
• Languages: English
• ISSNs: 1388-0209

Abstract

Abstract: Context: Xiaoer lianhuaqinqgan (XELH), developed based on Lianhua Qingwen (LHQW) prescription, contains 13 traditional Chinese medicines. It has completed the investigational new drug application to treat respiratory viral infections in children in China. Objective: This study demonstrates the pharmacological effects of XELH against viral pneumonia. Materials and methods: The antiviral and anti-inflammatory effects of XELH were investigated in vitro using H3N2-infected A549 and LPS-stimulated RAW264.7 cells and in vivo using BALB/c mice models of influenza A virus (H3N2) and respiratory syncytial virus (RSV)-infection. Mice were divided into 7 groups ( n = 20): Control, Model, LHQW (0.5 g/kg), XELH-low (2 g/kg), XELH-medium (4 g/kg), XELH-high (8 g/kg), and positive drug (20 mg/kg oseltamivir or 60 mg/kg ribavirin) groups. The anti-inflammatory effects of XELH were tested in a rat model of LPS-induced fever and a mouse model of xylene-induced ear edoema. Results: In vitro, XELH inhibited the pro-inflammatory cytokines and replication of H1N1, H3N2, H1N1, FluB, H9N2, H6N2, H7N3, RSV, and HCoV-229E viruses, with (IC50 47.4, 114, 79, 250, 99.2, 170, 79, 62.5, and 93 μg/mL, respectively). In vivo, XELH reduced weight loss and lung index, inhibited viral replication and macrophage M1 polarization, ameliorated lung damage, decreased inflammatory cell infiltration and pro-inflammatory cytokines expression in lung tissues, and increased the CD4 + /CD8 + ratio. XELH inhibited LPS-induced fever in rats and xylene-induced ear edoema in mice. Conclusion: XELH efficacy partially depends on integrated immunoregulatory effects. XELH is a promising therapeutic option against childhood respiratory viral infections.